Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab′)2 for efficient lysis of p185HER2 overexpressing tumor cells-Reference-Cited by-同舟云学术

Engineering high affinity humanized anti-p185HER2/anti-CD3 bispecific F(ab′)2 for efficient lysis of p185HER2 overexpressing tumor cells

Published:1995-07-28 Issue:3 Volume:62 Page:319-324
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Zhu Zhenping,Lewis Gail D.,Carter Paul

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference29 articles.

1. Distinctive functional characteristics of human „T” lymphocytes defined by E rosetting or a monoclonal anti-T cell antibody

2. Lysis of malignant B cells from patients with B-chronic lymphocytic leukemia by autologous T cells activated with CD3 x CD19 bispecific antibodies in combination with bivalent CD28 antibodies

3. , , , , , , , , , and , Adoptive immunotherapy of ovarian carcinoma with bs-mAb-targeted lymphocytes: a multicenter study. Int. J. Cancer (Suppl. 7), 78–81 (1992).

4. Humanization of an anti-p185HER2 antibody for human cancer therapy.

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tuning the potency and selectivity of ImmTAC molecules by affinity modulation;Clinical and Experimental Immunology;2023-11-01

2. Tuning the potency and therapeutic window of ImmTAC molecules by affinity modulation;2022-11-04

3. Facile Generation of Potent Bispecific Fab via Sortase A and Click Chemistry for Cancer Immunotherapy;Cancers;2021-09-10

4. Targeting a neoantigen derived from a common TP53 mutation;Science;2021-03-05

5. Bispecific antibodies targeting mutant RAS neoantigens;Science Immunology;2021-03-04